<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pneumococcal pneumonia in patients requiring hospitalization</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pneumococcal pneumonia in patients requiring hospitalization</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pneumococcal pneumonia in patients requiring hospitalization</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel M Musher, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elaine I Tuomanen, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas M File, Jr, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheila Bond, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 01, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Streptococcus pneumoniae </em>(pneumococcus) is the most commonly identified bacterial cause of community-acquired pneumonia (CAP). Mortality associated with pneumococcal pneumonia in hospitalized patients is high, ranging from 12 to 30 percent. Risk for severe infection, complications, and mortality are highest among older patients with chronic illnesses, particularly when complications, such as bacteremia are present.</p><p>This topic reviews pneumococcal pneumonia that requires hospitalization as distinguished from other forms of CAP. An overview of CAP, its diagnosis, and treatment are discussed separately. (See  <a class="medical medical_review" href="/d/html/7032.html" rel="external">"Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults"</a> and  <a class="medical medical_review" href="/d/html/7031.html" rel="external">"Treatment of community-acquired pneumonia in adults in the outpatient setting"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H2954893517"><span class="h2">Prevalence</span><span class="headingEndMark"> — </span>Pneumococcus has historically been the most common cause of pneumonia, by far [<a href="#rid1">1</a>], and remains the most common bacterial cause of community-acquired pneumonia (CAP) leading to hospitalization of adults today. In the United States, 5 to 15 percent of CAP cases have been attributed to pneumococcus [<a href="#rid2">2-4</a>]. However, more recent quantitative molecular [<a href="#rid5">5</a>] and bacteriologic data [<a href="#rid6">6</a>] indicate that this is an underestimate and suggest that 20 to 25 percent of cases may be due to pneumococcus [<a href="#rid5">5,6</a>]. This percentage is higher in Europe [<a href="#rid7">7-10</a>] and is even higher in developing countries [<a href="#rid11">11</a>].</p><p>In the preantibiotic era, all pneumonia was community acquired, and <em>S. pneumoniae</em> was responsible for more than 90 percent of cases [<a href="#rid1">1</a>]. The median age at onset of infection was in the upper 30s, contrasted to data at the end of the twentieth century showing a median age of 70 [<a href="#rid12">12</a>]. Even as other causative organisms of CAP were demonstrated (eg, influenza, <em>Mycoplasma</em>, other respiratory viruses, <em>Haemophilus,</em> <em>Moraxella, </em>and <em>Chlamydia </em>spp), pneumococcus continued to be the major cause of pneumonia in adults through the 1960s. Studies since then have shown a declining proportion of pneumonia to be due to this organism [<a href="#rid7">7</a>].</p><p>Factors that have contributed to the decline in <em>S. pneumoniae</em> as a cause of CAP in the United States include the widespread acceptance of pneumococcal vaccines by older adults, a substantial reduction in cigarette smoking by adults (these two factors likely distinguish the United States from Europe), and the universal use of pneumococcal conjugate vaccines in children. The impact of pneumococcal vaccination on the incidence of pneumonia is discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults"</a> and  <a class="medical medical_review" href="/d/html/6053.html" rel="external">"Pneumococcal vaccination in children"</a>.)</p><p>The true prevalence of pneumococcus as a cause of CAP may be higher than the studies above suggest. Most studies of CAP have failed to identify a causative organism in over 50 percent of cases and it is likely that pneumococcus is responsible for some proportion of these cases [<a href="#rid13">13</a>]. The principal reason for failing to recognize <em>S. pneumoniae </em>as a cause of pneumonia is methodologic. Blood cultures are positive in no more than 20 to 25 percent of pneumococcal pneumonia [<a href="#rid1">1,13</a>], and the urine antigen test in nonbacteremic disease has only moderate sensitivity (see <a class="local">'Diagnosis'</a> below); thus, the diagnosis of pneumococcal pneumonia rests, in many cases, on sputum Gram stain and culture.</p><p>Many patients with pneumonia are unable to provide a valid sputum sample (rather than "spit" or saliva) at admission and, after 18 to 24 hours of antibiotic treatment, the yield of sputum Gram stain and culture declines greatly [<a href="#rid14">14</a>]. Prospective studies of pneumococcal pneumonia [<a href="#rid15">15,16</a>] have found approximately equal numbers of bacteremic and nonbacteremic cases, suggesting that there are two additional cases of nonbacteremic pneumococcal pneumonia for every one that is recognized. In one study evaluating hospitalized patients who were able provide a purulent sputum at hospital admission (or soon after), a microbiologic diagnosis was made in 95 percent of cases [<a href="#rid6">6</a>]. S pneumoniae accounted for approximately 25 percent.</p><p class="headingAnchor" id="H1203981299"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>Approximately 90 percent of patients have one or more underlying condition(s) that probably contributes to susceptibility of developing the infection [<a href="#rid12">12</a>]. These conditions include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extremes of age</strong> − Pneumococcal pneumonia occurs most frequently in infants and toddlers and in older adults, although the success of protein-conjugate pneumococcal vaccine has greatly reduced the incidence of pneumococcal disease in the former age group.</p><p></p><p class="bulletIndent1">It is suggested that the global burden of pneumococcal disease will increase as life expectancy increases [<a href="#rid17">17</a>]. The effect of older age is multifactorial, including (but not limited to) increased likelihood of unrecognized aspiration and/or decreased clearance of aspirated nasopharyngeal bacteria, decreased cytokine production and/or decreased responsiveness to interleukin 1 and tumor necrosis factor-alpha, and suboptimal nutritional status [<a href="#rid18">18</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Crowded living conditions</strong> − The incidence of pneumococcal pneumonia has been shown to be greatly increased in South African miners [<a href="#rid19">19</a>] and newly recruited military troops [<a href="#rid20">20</a>] who have in common crowded living conditions and physical and emotional stress. Very close contact at work, for example, in shipyards, has been implicated [<a href="#rid21">21</a>]. Outbreaks of pneumococcal pneumonia have also been described in shelters [<a href="#rid22">22</a>], jails [<a href="#rid23">23</a>], and nursing homes and long-term care facilities [<a href="#rid24">24,25</a>] where similar conditions may prevail.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Race/ethnicity</strong> − Pneumococcal pneumonia occurs more frequently in Black Americans and Native Americans than in the White American population [<a href="#rid26">26-28</a>]. While it is difficult to distinguish environmental and other contributing factors from genetic determinants, susceptibility in these groups may involve genetic determinants.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Viral infection</strong> − Influenza infection greatly predisposes to secondary pneumococcal pneumonia [<a href="#rid29">29</a>], and infection by other viruses probably does, as well, as evidenced by the prevalence of viral and pneumococcal coinfection [<a href="#rid2">2,3,5,6</a>]. The principal explanation is damaged clearance of bacteria that have bypassed usual (but not constant) protection of a closed glottis. Other explanations include increased expression of genes that govern growth and metabolism of pneumococci during coinfection with influenza virus [<a href="#rid30">30</a>] and the ability of pneumococci to carry viral particles on its surface during aerosol transmission [<a href="#rid31">31</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alcohol use disorder</strong> − For more than a century, alcohol use disorder has been highly associated with susceptibility to pneumococcal pneumonia [<a href="#rid1">1,27,32</a>]. The reasons for this increased susceptibility are complex and differ for acute versus chronic alcohol abuse [<a href="#rid32">32</a>]. Multiple elements of host defenses are impaired in alcohol abuse including decreased cough and epiglottis reflex, defects in mucociliary clearance, suppression of cytokine and chemokine responses, and numerous aspects of neutrophil function (adhesion, migration to site of infection, and killing of pneumococci). With chronic alcohol use disorder, malnutrition and liver disease play further contributory roles.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cigarette smoking</strong> − Nasopharyngeal colonization is increased in cigarette smokers and even in children of parents who smoke [<a href="#rid33">33</a>]. Pneumococcal pneumonia (specifically, invasive pneumococcal disease, most of which is due to pneumonia) is highly associated with cigarette smoking (odds ratio [OR] 4.1, 95% CI 2.4-7.3) and with passive smoke exposure (OR 2.5, 95% CI 1.2-5.1) [<a href="#rid34">34</a>]. A dose-response relationship was demonstrable for number of cigarettes smoked per day, packs per year of smoking, and time since quitting. Presumably, damaged pulmonary clearance is largely responsible, but other lifestyle factors also play a role.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>COPD and other pulmonary disorders</strong> − Patients with chronic obstructive pulmonary disease (COPD) have increased rates of hospitalization due to pneumococcal pneumonia [<a href="#rid35">35</a>]. There are conflicting data regarding the risk among patients with asthma [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Splenectomy</strong> – Patients who have undergone surgical splenectomy or autosplenectomy (eg, as a result of sickle cell disease) are at increased risk of overwhelming pneumococcal infection unless they have antibody to the infecting serotype because the spleen plays a principal role in removing unopsonized bacteria from the bloodstream. (See  <a class="medical medical_review" href="/d/html/1404.html" rel="external">"Clinical features, evaluation, and management of fever in patients with impaired splenic function", section on 'Streptococcus pneumoniae (pneumococcus)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunocompromise</strong> − The principal host defense against pneumococcal pneumonia is antibody to pneumococcal capsular polysaccharide, thus, any condition that reduces the antibody response to new antigens is highly likely to predispose to pneumococcal pneumonia. Historically, in addition to congenital or acquired agammaglobulinemia, multiple myeloma and lymphoma were the best recognized examples of this association [<a href="#rid37">37,38</a>]. HIV infection was subsequently recognized as a major predisposing condition; early in the AIDS era, the nearly 200-fold increase in age-adjusted invasive pneumococcal disease in San Francisco was due to the dramatically increased numbers of HIV-infected patients in that population [<a href="#rid39">39,40</a>]. An association with systemic lupus erythematosus has been documented [<a href="#rid41">41</a>]. The incidence of pneumococcal pneumonia has been shown to be increased in malignancy [<a href="#rid42">42</a>], hemodialysis [<a href="#rid42">42</a>], transplantation [<a href="#rid43">43-45</a>] and, in particular, hematopoietic cell transplantation complicated by chronic graft-versus-host disease [<a href="#rid42">42,46</a>]. The incidence of pneumococcal pneumonia is greatly increased by a variety of mechanisms, only one of which is the well-recognized autosplenectomy that results from poor flexibility of sickle cells to pass through splenic capillaries [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other conditions</strong> − Opioid use [<a href="#rid48">48</a>] and welding [<a href="#rid49">49</a>] are independent risk factors for pneumococcal disease.</p><p></p><p class="headingAnchor" id="H2381587611"><span class="h1">PATHOGENESIS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Human to human transmission</strong> – <em>S. pneumoniae </em>is an exclusively human pathogen and is spread from person to person by aerosol inhalation or close contact.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nasopharyngeal colonization</strong> – Colonization of the nasopharynx results when pneumococcal surface proteins (eg, pneumococcal surface protein A, choline binding protein C) [<a href="#rid50">50,51</a>] react with ligands on human mucosal epithelial cells [<a href="#rid52">52</a>]. At any given time, 25 to 50 percent of children and 5 to 10 percent of adults are colonized with pneumococcus in the nasopharynx. Several serotypes may be carried at the same time. Children carry a larger number of organisms (the "bacterial burden" is much greater), and family studies have shown that children generally serve as the major source for the spread of pneumococci to adults [<a href="#rid53">53</a>]. Once colonized, healthy adults continue to carry pneumococci for 4 to 12 weeks; carriage persists longer in immunocompromised persons.</p><p></p><p class="bulletIndent1">Colonization of the nasopharynx by pneumococ<em>c</em>us is not a passive process. Bacterial antigen is taken up by dendritic cells and, within 10 to 14 days, antibody to capsular polysaccharide is detected in serum [<a href="#rid54">54</a>]. This antibody is highly protective, and if pneumococcal disease occurs at a later time, it generally follows acquisition of a new serotype [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aspiration leading to pneumonia</strong> – Pneumonia develops when nasopharyngeal secretions containing pneumococci are carried into the lungs (ie, aspiration) and are not cleared rapidly and effectively. Aspiration is successfully prevented during waking hours by the glottis but regularly occurs during sleep, being especially prevalent in older and more frail adults [<a href="#rid56">56</a>]. Normal clearance mechanisms will greatly reduce the likelihood of disease, but may be overcome by aspiration of a sufficiently large bacterial inoculum [<a href="#rid57">57</a>]. Clearance mechanisms may be damaged by a broad range of factors including suppression of cough by alcohol or drugs and by any chronic inflammatory condition affecting the airways, such as cigarette smoking, viral respiratory infections, etc, which produce mucus and/or damage ciliary clearance.</p><p></p><p class="bulletIndent1">Within the alveolus, pneumococci encounter antimicrobial peptides and shed the polysaccharide capsule [<a href="#rid58">58</a>]. This reveals pili and surface proteins that can bind to host epithelial cell carbohydrates and receptors. As pneumococci multiply in the alveoli and spread through the pores of Cohn or via tertiary bronchioles, pneumonia progresses. To disseminate to other organs, bacteria enter alveolar type II cells by binding to the receptor for platelet-activating factor (PAF) and cross into capillaries [<a href="#rid59">59</a>]. This attachment occurs through bacterial display of surface-localized phosphorylcholine, a chemical constituent shared between the bacteria and the human chemokine PAF. The host innate defense element C-reactive protein binds to phosphorylcholine blocking bacterial entry and facilitating phagocytosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Robust inflammatory response</strong> – The inflammatory response to pneumococcal replication in the alveoli is intense. Pneumolysin, a pore-forming toxin with the capacity to kill host cells contributes substantially to alveolar damage [<a href="#rid60">60</a>]. Bacterial components, especially peptidoglycan, activate innate Toll-like receptors that trigger strong signaling to induce cytokine production [<a href="#rid61">61,62</a>]. Bronchoalveolar lavage fluid in pneumonia contains high amounts of tumor necrosis factor, interleukins 1 and 6, and nitric oxide, reflective of strong recruitment of leukocytes to the infected focus [<a href="#rid63">63</a>]. Alveoli fill with plasma, white blood cells, and bacteria producing the inflammatory exudate that is seen as opacities on chest radiograph and that causes ventilation-perfusion defects. There is little permanent tissue destruction or necrosis during this process, however, perhaps explaining why patients recover fully from these lesions, although, infrequently, cavitation or necrotizing pneumonia occurs [<a href="#rid64">64,65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential invasive infection</strong> – Invasive pneumococcal infection is defined by the detection of pneumococci in normally sterile body sites. Bacteremia, by definition an invasive infection, is detected by results of blood culture  (<a class="graphic graphic_diagnosticimage graphicRef65658" href="/d/graphic/65658.html" rel="external">image 1</a> and <a class="graphic graphic_diagnosticimage graphicRef64692" href="/d/graphic/64692.html" rel="external">image 2</a>). Other organs can become infected leading to complications such as meningitis, arthritis, myocarditis, and endocarditis. (See  <a class="medical medical_review" href="/d/html/3168.html" rel="external">"Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia in adults"</a>.)</p><p></p><p class="headingAnchor" id="H14"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H3642059757"><span class="h2">Pneumococcal pneumonia</span></p><p class="headingAnchor" id="H2120102931"><span class="h3">Symptoms</span><span class="headingEndMark"> — </span>The "classic" syndrome associated with pneumococcal pneumonia is acute onset fever, chills, cough, pleuritic chest pain, and rusty-colored sputum [<a href="#rid1">1</a>]. This description is derived from reports in the preantibiotic era when pneumococcal pneumonia more often affected young adults who likely had robust immune responses to infection. This syndrome is now seen less frequently. Currently, the median age of patients with pneumococcal pneumonia is around 65 to 70 years. The onset is more insidious, often preceded by symptoms consistent with a viral illness for several days with a distinct deterioration when the bacterial infection sets in. Once symptoms of pneumonia appear, infection progresses fairly rapidly such that most patients who require hospitalization present within the next three days [<a href="#rid15">15,66,67</a>].</p><p>Based on studies, cough, shortness of breath, and subjective fever and/or chills are present in more than 80 percent of adults with pneumococcal pneumonia [<a href="#rid12">12,15,66-70</a>]. Sputum production is variably present, more frequently in middle-aged men, especially those with chronic lung disease. Sputum is bloody (often described as rusty rather than frankly bloody because of the admixture of inflammatory exudate and red cells in the alveoli) in 15 percent of patients. About one-quarter of patients have chest pain and a similar number have confusion. Importantly, all these symptoms except for confusion tend to be less prominent in older adult patients (the persons in whom pneumococcal pneumonia is most common) [<a href="#rid67">67</a>]. Some older patients may just "look ill," become confused, or "not be themselves." The less prominent manifestations of pneumococcal pneumonia in older adults probably reflects generation of lesser amounts of inflammatory cytokines and/or lower responsiveness to those that are produced. Diarrhea or vomiting, observed in some patients, result from the action of circulating cytokines on the gut.</p><p class="headingAnchor" id="H2496519581"><span class="h3">Physical examination</span><span class="headingEndMark"> — </span>On physical examination, patients with pneumococcal pneumonia are generally ill-appearing [<a href="#rid15">15</a>]. Tachypnea and tachycardia are common. Because of perfusion/ventilation mismatch, up to one-half have abnormally low partial pressure of oxygen. Somewhat surprisingly to most clinicians, fever, if defined as body temperature exceeding 99.4°F, is seen in fewer than 50 percent of cases, although the absence of fever, tachypnea, and tachycardia renders the diagnosis of pneumonia very unlikely [<a href="#rid71">71</a>].</p><p>Abnormal physical findings, including rales, increased fremitus, and/or dullness to percussion over the affected lung, may be found in the majority of cases. However, careful study of patients with community-acquired pneumonia (CAP) has shown that these, and other physical findings, are not consistently documented and that there may be substantial intraobserver difference in eliciting them [<a href="#rid71">71-73</a>].</p><p class="headingAnchor" id="H4125471970"><span class="h3">Laboratory findings</span><span class="headingEndMark"> — </span>In 10 to 30 percent of patients with bacteremic pneumococcal pneumonia, the admitting blood hemoglobin is &lt;10 g/dL. The white blood cell (WBC) count usually exceeds 10,000, and early (band) forms are seen in about 20 percent of cases. In one study, 10 percent of patients with pneumococcal pneumonia had WBC counts &lt;6000 and 8 percent had WBC counts &gt;25,000; 56 percent of patients with low WBC counts were bacteremic, and the mortality in these two groups was fivefold and threefold greater, respectively, than in all those with WBC counts between 6000 and 25,000 [<a href="#rid73">73</a>]. Bilirubin and liver enzymes may be mildly elevated; the pathogenesis of these abnormalities is multifactorial with hypoxia, cytokine release, involvement of the right lower lobe, and breakdown of red blood cells in the alveoli all playing a role. Albumin is low in more than 50 percent of patients. In some of these, malnutrition may have been a contributing cause, but in the great majority the low albumin has developed acutely as a result of the pneumonia [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H2272273532"><span class="h3">Chest imaging</span><span class="headingEndMark"> — </span>Abnormal findings in pneumococcal pneumonia range from "increased markings" or "possible atelectasis" to infiltration or lobar consolidation with air bronchograms. In some cases, abnormalities are only seen on computed tomography (CT) scan, which are increasingly ordered routinely in emergency departments. Ultrasound is increasingly being used to diagnose pneumonia, but often by physicians who lack appropriate training to correctly obtain and interpret them.</p><p>Dense consolidation of a segment or lobe is associated with bacteremia and more severe disease [<a href="#rid74">74</a>]. Necrotizing changes or frank abscesses are uncommon. In a study of 351 patients with pneumococcal pneumonia, necrotizing changes were not reported in any original chest radiograph readings and in 6 of 136 (4.4 percent) of initial CT readings [<a href="#rid65">65</a>]. Even upon rereading, only 8 of 351 (2.3 percent) chest radiographs and 15 of 136 (11 percent) chest CTs showed necrotizing changes. Frank lung abscess is rarely reported [<a href="#rid75">75</a>].</p><p class="headingAnchor" id="H2852601542"><span class="h2">Complications</span></p><p class="headingAnchor" id="H1375654489"><span class="h3">Pleural effusion and empyema</span><span class="headingEndMark"> — </span>Approximately one-third of patients with pneumococcal pneumonia have a pleural effusion that is detectable by special studies, but only a fraction of these have enough fluid to do a pleurocentesis [<a href="#rid76">76</a>]. When sufficient fluid is present in a patient with pneumococcal pneumonia, pleurocentesis should be performed. (See  <a class="medical medical_review" href="/d/html/6702.html" rel="external">"Epidemiology, clinical presentation, and diagnostic evaluation of parapneumonic effusion and empyema in adults"</a>.)</p><p>Empyema (frankly purulent pleural fluid) has always been the most common serious pulmonary complication of pneumococcal pneumonia, occurring in approximately 5 percent of cases. Whether organisms reach the pleural space from local extension or from bacteremic spread has not been established. In either scenario, the presence of empyema alters management, mandating prompt drainage and prolonged antibiotic treatment. (See  <a class="medical medical_review" href="/d/html/119384.html" rel="external">"Management and prognosis of parapneumonic pleural effusion and empyema in adults"</a>.)</p><p class="headingAnchor" id="H1119500595"><span class="h3">Bacteremia</span><span class="headingEndMark"> — </span>Bacteremia complicates pneumococcal pneumonia in approximately 25 percent of cases [<a href="#rid1">1,13</a>]. The onset of illness also tends to be more acute, fever and pulse rates are higher, and there is a higher likelihood of sepsis. Multilobar infiltrates and pleural effusions are more common as are, expectedly, complications such as septic arthritis or meningitis.</p><p>Bacteremic disease is more common in younger patients (often in their mid-50s) than nonbacteremic disease (often in their mid to upper 60s). Patients with alcohol use disorder are more likely, and those with chronic obstructive pulmonary disease are less likely, to have bacteremia when they have pneumococcal pneumonia. Bacteremic pneumonia tends to be more acute in onset with a shorter time from onset of symptoms to admission. In-hospital mortality is about 12 to 15 percent and 90-day mortality is about 25 to 30 percent in bacteremic patients, in each case about twice as high as for nonbacteremic patients [<a href="#rid15">15,16,70</a>].</p><p class="headingAnchor" id="H878133702"><span class="h3">Other infectious complications</span><span class="headingEndMark"> — </span>Other life-threatening complications of pneumococcal pneumonia result from bacteremia, and include meningitis, endocarditis, pericarditis, myocarditis, septic arthritis, and peritonitis. (See  <a class="medical medical_review" href="/d/html/3168.html" rel="external">"Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia in adults"</a>.)</p><p class="headingAnchor" id="H552277745"><span class="h3">Cardiac events and other noninfectious complications</span><span class="headingEndMark"> — </span>Observational data shows a strong association with acute cardiac events and pneumococcal pneumonia. Short-term cardiac complications occur in one-third of patients, with myocardial infarction reported in 7 percent of cases, new onset of a major cardiac arrhythmia (atrial fibrillation in most) in 5 percent, and new onset or worsening congestive heart failure in 8 percent of cases [<a href="#rid15">15,77-79</a>]. Compared with CAP patients without acute cardiac events, CAP patients with acute cardiac events have longer time to clinical stability, increased rates of clinical failure, and increased 30- and 90-day mortality [<a href="#rid80">80,81</a>]. Mortality in patients with a cardiac event is far greater than for those who do not have such an event. Increased risk for a cardiac event extends to at least a year following pneumonia.</p><p>Subsequent studies have shown this association in patients with all-cause CAP [<a href="#rid80">80</a>], other bacterial infections [<a href="#rid82">82</a>], and, to a lesser extent, influenza [<a href="#rid83">83</a>]. The general explanations have been that: (1) inflammation elsewhere in the body increases inflammation in a vulnerable plaque, leading to rupture and acute obstruction of a coronary artery, or (2) increased physiologic stress with increased demand for oxygen, possibly together with decreased oxygen supply due to ventilation/perfusion mismatch cause acute ischemia [<a href="#rid84">84</a>]. An additional mechanism has been documented specifically for pneumococcal infection by the finding of microcolonies of pneumococci in cardiac muscle in animals that have been infected with <em>S. pneumoniae </em>or in humans who have died from pneumococcal infection [<a href="#rid85">85</a>]. These foci of bacteria lead to focal death of cardiomyocytes, permanent scarring, and subsequent heart failure or arrhythmias.</p><p>Pneumococcal pneumonia has also been associated with new-onset stroke [<a href="#rid86">86,87</a>].</p><p class="headingAnchor" id="H3933219742"><span class="h2">Long-term outcome</span><span class="headingEndMark"> — </span>An increased risk for mortality persists for up to 10 years after pneumococcal infection, and risk is greater throughout this time in proportion to the severity of infection [<a href="#rid88">88</a>]. This phenomenon is likely due to epigenetic changes that result from the acute infection [<a href="#rid89">89</a>].</p><p class="headingAnchor" id="H1103383691"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H2461294134"><span class="h2">Approach to diagnosis</span><span class="headingEndMark"> — </span>For most hospitalized patients with community-acquired pneumonia (CAP), we obtain blood cultures, sputum Gram stain and culture, and a urine pneumococcal antigen test. The results of these tests help direct therapy, identify complications, and inform prognosis  (<a class="graphic graphic_table graphicRef118966" href="/d/graphic/118966.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/7032.html" rel="external">"Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults"</a>.)</p><p>While the definitive diagnosis of pneumococcal pneumonia requires culture of pneumococcus from a normally sterile site (eg, blood or pleural fluid), the detection of pneumococcus in sputum culture and/or a positive urine pneumococcal antigen test in a patient who presents with pneumonia is generally sufficient to make a presumptive diagnosis and direct therapy. The detection of gram-positive cocci singly and in pairs in a high-quality sputum specimen obtained from a patient with CAP who has not received antibiotics for more than 18 hours is also highly suggestive of pneumococcal pneumonia [<a href="#rid14">14,90</a>].</p><p class="headingAnchor" id="H2265415073"><span class="h2">Microbiologic testing</span></p><p class="headingAnchor" id="H1186561529"><span class="h3">Sputum Gram stain and culture</span><span class="headingEndMark"> — </span>The sensitivity and specificity of sputum Gram stain and culture are dependent upon the quality of the sputum sample obtained and, if antibiotics have been begun, the duration. Although the value of sputum Gram stain and culture for the diagnosis of bacterial CAP has been debated [<a href="#rid91">91,92</a>], there are diagnostic and therapeutic benefits of establishing a microbiologic diagnosis. A meta-analysis of 24 studies indicated Gram stain of a good-quality sputum sample was highly specific to diagnose pneumococcal disease (sensitivity of 0.69 and specificity of 0.91) [<a href="#rid93">93</a>]. (See  <a class="medical medical_review" href="/d/html/7018.html" rel="external">"Sputum cultures for the evaluation of bacterial pneumonia"</a>.)</p><p>In patients with pneumococcal pneumonia, alveoli fill with plasma and white blood cells (WBCs) in response to the presence of pneumococci. When this material is coughed up, it seems only logical that bacteria should be readily detected. However, reported detection rates are variable. This may relate to the quality of the sputum specimens obtained and whether antibiotics were administered prior to obtaining a sputum specimen in available studies. For example, in one study of 105 patients with bacteremic pneumococcal pneumonia, the presence of pneumococci was detected by sputum Gram stain in 31 percent of patients and by culture in 44 percent [<a href="#rid14">14</a>]. However, in 20 percent of those cases, no sputum was submitted to the laboratory; in an additional 15 percent, the sputum sample that was submitted was rejected because it was inadequate. When these cases were removed from the denominator, the sensitivity of Gram stain and culture rose to 57 and 79 percent, respectively. With exclusion of patients who had received antibiotics for &gt;24 hours, sensitivity of Gram stain and culture rose to 63 and 86 percent, respectively; for patients who had received no antibiotics, these values were 80 and 93 percent, respectively [<a href="#rid14">14</a>]. In a recent study that was confined to patients who produced a high-quality sputum sample, microscopic examination yielded results that were consistent with final microbiologic findings in 98 percent of cases in which an etiologic agent (bacterial, viral, or coinfection) was identified [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H3492346549"><span class="h3">Urine antigen detection</span><span class="headingEndMark"> — </span>The urine pneumococcal antigen test detects cell wall polysaccharides of <em>S. pneumoniae</em>. The most commonly used assay is the Binax NOW assay. When introduced in 2003, this assay detected about 70 percent of patients with pneumococcal pneumonia [<a href="#rid94">94</a>]. Subsequent studies found similar results, with greater positivity in bacteremic disease and lower positivity in nonbacteremic disease [<a href="#rid95">95</a>]. The specificity of the assay in adults exceeds 98 percent [<a href="#rid95">95</a>]. False positives occur in 10 to 20 percent of healthy young children who have nasopharyngeal colonization [<a href="#rid96">96,97</a>], and the test is not recommended in children.</p><p>To augment the sensitivity of the Binax NOW assay, serotype-specific tests that detect capsular polysaccharide were developed [<a href="#rid98">98-100</a>]. However, the tests that are available detect serotypes that are contained in the 13-valent conjugate <a class="drug drug_general" data-topicid="9784" href="/d/drug information/9784.html" rel="external">pneumococcal polysaccharide vaccine</a>; these serotypes have rapidly declined in the population with widespread use of the conjugate vaccine in children. Thus, this assay is unlikely to add value to the existing diagnostic armamentarium.</p><p class="headingAnchor" id="H3666337145"><span class="h3">Blood cultures</span><span class="headingEndMark"> — </span>Blood cultures are an important part of the diagnostic evaluation and are positive in 20 to 25 percent of cases of pneumococcal pneumonia [<a href="#rid1">1,13</a>]. The presence of bacteremia proves the etiologic diagnosis and helps define the severity of infection, the likelihood of developing complications, and the overall prognosis [<a href="#rid15">15,16,70</a>]. </p><p class="headingAnchor" id="H121202145"><span class="h3">Multiplex panels</span><span class="headingEndMark"> — </span>Multiplex polymerase chain reaction (PCR) assays, which detect arrays of respiratory bacterial pathogens including <em>S. pneumoniae</em> and several antibiotic-resistance genes, are approved for the diagnosis of pneumonia using bronchoalveolar lavage specimens in the United States [<a href="#rid101">101-103</a>]. Studies evaluating these assays have included patients with CAP and hospital- or ventilator-acquired pneumonia; their usefulness for the diagnosis of pneumococcal pneumonia is uncertain. We have also evaluated a microbial cell-free plasma next-generation sequencing test for pathogen detection in hospitalized patients with pneumonia; in a small sample, the rates of false positives and false negatives (approximately one-third of each) were far too high to make this test reliable [<a href="#rid104">104</a>]. </p><p class="headingAnchor" id="H655504915"><span class="h3">Other tests</span><span class="headingEndMark"> — </span>A variety of other tests have been used to diagnose pneumococcal pneumonia, including immunoglobulin (Ig)G antibodies to capsular polysaccharides, the autolysin LytA, and pneumolysin [<a href="#rid105">105,106</a>] and several quantitative PCR assays [<a href="#rid5">5,105-109</a>]. None is well validated or routinely used. </p><p class="headingAnchor" id="H3394365137"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H625825810"><span class="h2">Empiric therapy</span><span class="headingEndMark"> — </span>Empiric treatment regimens for patients hospitalized with community-acquired pneumonia (CAP) are routinely designed to include an agent that specifically targets pneumococcus, such as <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> or a respiratory fluoroquinolone [<a href="#rid110">110</a>].</p><p>We give intravenous (IV) antibiotics for the initial treatment of hospitalized patients. Shock may develop before oral antibiotic antibiotics are absorbed, and there is always some uncertainty about gastrointestinal absorption of oral antibiotics in severely ill patients. Upon clinical improvement, IV antibiotics can be rapidly transitioned to oral therapy. (See  <a class="medical medical_review" href="/d/html/117561.html" rel="external">"Overview of community-acquired pneumonia in adults"</a> and  <a class="medical medical_review" href="/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization"</a>.)</p><p class="headingAnchor" id="H2269180617"><span class="h2">Directed therapy</span><span class="headingEndMark"> — </span>Once a diagnosis of pneumococcal pneumonia is made, treatment should be tailored to target pneumococcus. We generally consider culture of pneumococcus from sputum and/or blood or a positive urine pneumococcal antigen to be sufficient to establish the etiologic diagnosis and tailor therapy. For patients whose sputum Gram stain suggests pneumococcal infection (ie, presence of gram-positive cocci singly and in pairs in high-quality sputum sample), we are willing to treat specifically for this organism; other experts prefer to await results of the culture, both to confirm the diagnosis of pneumococcal pneumonia and to exclude the presence of other pathogens before narrowing therapy.</p><p>Initial antibiotic selection and approach to management for patients with pneumococcal pneumonia varies based on the severity of illness, presence of complications, concern for drug-resistance, host susceptibilities, and patient allergies. Interpretive breakpoints for selected antibiotics are in this table  (<a class="graphic graphic_table graphicRef63881" href="/d/graphic/63881.html" rel="external">table 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preferred treatment</strong> – For most patients with pneumococcal pneumonia (with or without bacteremia) in the United States, we suggest <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> (1 g IV every 24 hours). Across the United States, 98 percent of pneumococcal isolates are susceptible (minimum inhibitory concentration [MIC] ≤1 mcg/mL) or intermediately susceptible (MIC &gt;1 and ≤2 mcg/mL) to ceftriaxone [<a href="#rid111">111</a>]. At 1 g per day, ceftriaxone will provide a serum level above 2 mcg/mL for a 24-hour period. However, in some regions within the United States (ie, the southeast and Pacific northwest) and, especially, in other regions on the world (eg, Eastern Europe and parts of Asia), ceftriaxone resistance rates are higher. (See  <a class="medical medical_review" href="/d/html/7034.html" rel="external">"Resistance of <i>Streptococcus pneumoniae</i> to beta-lactam antibiotics"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Concern for </strong><strong>ceftriaxone</strong><strong> resistance</strong> – When resistance to <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> is a concern based on susceptibility testing (MIC &gt;2 mcg/mL) or local epidemiology, we treat with an antibiotic from a class other than beta-lactams. Generally, we use a respiratory fluoroquinolone because susceptibility to fluoroquinolones remains stably high across regions. Depending on the MIC of the isolate, some experts might, instead, increase the dose of ceftriaxone to 1 g IV every 12 hours to overcome resistance.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="16088" href="/d/drug information/16088.html" rel="external">Ceftaroline</a> (a broad-spectrum IV late-generation cephalosporin) or <a class="drug drug_general" data-topicid="122343" href="/d/drug information/122343.html" rel="external">lefamulin</a> (an oral pleuromutilin antibiotic) could also be used to treat pneumococcal pneumonia caused by a ceftriaxone-resistant isolate; each drug has been shown to be reliably active against pneumococci in vitro [<a href="#rid112">112,113</a>] and effective for the treatment of pneumonia in clinical trials [<a href="#rid8">8,114-116</a>]. <a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">Linezolid</a> is an additional option. In vitro, pneumococci are also routinely susceptible to <a class="drug drug_general" data-topicid="95502" href="/d/drug information/95502.html" rel="external">dalbavancin</a>, <a class="drug drug_general" data-topicid="119253" href="/d/drug information/119253.html" rel="external">omadacycline</a>, and <a class="drug drug_general" data-topicid="118878" href="/d/drug information/118878.html" rel="external">eravacycline</a> [<a href="#rid117">117-119</a>].</p><p></p><p class="bulletIndent1">Interpretive breakpoints for selected antibiotics are in this table  (<a class="graphic graphic_table graphicRef63881" href="/d/graphic/63881.html" rel="external">table 2</a>). Pneumococcal resistance patterns and rates of pneumococci to <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> and other antibiotics vary regionally are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7034.html" rel="external">"Resistance of <i>Streptococcus pneumoniae</i> to beta-lactam antibiotics"</a> and  <a class="medical medical_review" href="/d/html/7028.html" rel="external">"Resistance of <i>Streptococcus pneumoniae</i> to the fluoroquinolones, doxycycline, and trimethoprim-sulfamethoxazole"</a> and  <a class="medical medical_review" href="/d/html/7033.html" rel="external">"Resistance of <i>Streptococcus pneumoniae</i> to the macrolides, azalides, and lincosamides"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta-lactam allergy or intolerance</strong> – For patients with pneumococcal pneumonia who cannot tolerate a third-generation cephalosporin due to allergy or other intolerance, we typically treat with a respiratory fluoroquinolone (ie, <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> 750 mg daily or <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a> 400 mg daily). Fluoroquinolones are equally effective as <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> but may have a higher adverse effect profile [<a href="#rid120">120</a>]. <a class="drug drug_general" data-topicid="122343" href="/d/drug information/122343.html" rel="external">Lefamulin</a> and <a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">linezolid</a> are other alternatives. Cross reactivity with <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a> and <a class="drug drug_general" data-topicid="16088" href="/d/drug information/16088.html" rel="external">ceftaroline</a> are thought to be rare, but these have not been extensively studied [<a href="#rid121">121,122</a>]; since other classes of drugs are available, these two drugs might best be avoided.</p><p></p><p class="bulletIndent1">Respiratory fluoroquinolones are also appropriate alternatives for patients with severe penicillin hypersensitivities (ie, angioedema and/or anaphylaxis, serious delayed reactions). Patients with milder penicillin allergies can be safely treated with <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> [<a href="#rid121">121</a>]  (<a class="graphic graphic_algorithm graphicRef100745" href="/d/graphic/100745.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/111361.html" rel="external">"Choice of antibiotics in penicillin-allergic hospitalized patients"</a> and  <a class="medical medical_review" href="/d/html/2087.html" rel="external">"Allergy evaluation for immediate penicillin allergy: Skin test-based diagnostic strategies and cross-reactivity with other beta-lactam antibiotics"</a> and  <a class="medical medical_review" href="/d/html/100191.html" rel="external">"Penicillin allergy: Delayed hypersensitivity reactions"</a> and  <a class="medical medical_review" href="/d/html/2073.html" rel="external">"Penicillin allergy: Immediate reactions"</a>.)</p><p></p><p><strong>Complications</strong> – Modifications to this approach are needed for complications other than bacteremia.</p><p class="bulletIndent1"><span class="glyph">●</span>When there is concern for parapneumonic effusion or empyema, thoracentesis is required for diagnosis, and the effusion or empyema should be drained promptly. (See  <a class="medical medical_review" href="/d/html/119384.html" rel="external">"Management and prognosis of parapneumonic pleural effusion and empyema in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When there is a concern for concurrent pneumococcal meningitis, the dose of <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> is 2 g every 12 hours, and <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> should be added, as a small number of strains are resistant to ceftriaxone. Treatment can then be continued with one or both drugs depending upon susceptibility of the organism and is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1283.html" rel="external">"Treatment of bacterial meningitis caused by specific pathogens in adults", section on 'Streptococcus pneumoniae'</a>.)</p><p></p><p class="headingAnchor" id="H3444629258"><span class="h2">Adjunctive macrolide therapy</span><span class="headingEndMark"> — </span>For patients with severe pneumococcal pneumonia, some experts add a macrolide (ie, <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>) to <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> for the first few days of therapy. The macrolide is not added for its antibacterial effect, since approximately 20 percent of pneumococci are macrolide-resistant, nor for any synergistic effect [<a href="#rid123">123</a>]. Rather, macrolides suppress production of transcription factors nuclear factor kappa B (NFkB) and activator protein (AP)-1, thereby inhibiting intracellular signaling pathways. These effects reduce generation of inflammatory cytokines, especially interleukin 8. Macrolides also inhibit production of leukotriene (LT)-B4 and expression of adhesion molecules Mac-1 and ICAM-1 [<a href="#rid124">124</a>]. These effects dampen inflammatory responses and may confer survival benefit.</p><p>This survival benefit appears to be most pronounced in patients with severe illness and has been detected in several observational studies comparing outcomes in patients treated with beta-lactam monotherapy versus combination therapy with a macrolide [<a href="#rid125">125-128</a>]. In one cohort study evaluating 844 patients with pneumococcal bacteremia (usually due to pneumococcal pneumonia), combination therapy with a beta-lactam and a macrolide was associated with reduced 14-day mortality when compared with beta-lactam monotherapy (23 versus 55 percent) [<a href="#rid126">126</a>].</p><p class="headingAnchor" id="H1361711758"><span class="h2">Adjunctive glucocorticoids</span><span class="headingEndMark"> — </span>The same basic principle of dampening an excessive immune response underlies the recommendation that adjunctive glucocorticosteroids be used to treat selected patients who are severely ill with CAP and refractory septic shock [<a href="#rid110">110</a>]. This is discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization"</a> and  <a class="medical medical_review" href="/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization", section on 'Adjunctive glucocorticoids'</a>.)</p><p class="headingAnchor" id="H279390941"><span class="h2">Transition to oral therapy</span><span class="headingEndMark"> — </span>After the patient's condition has stabilized, IV therapy can be transitioned to oral therapy (stepdown therapy). Selection of an oral antibiotic depends on the susceptibility of the isolate.</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with isolates that are susceptible or intermediately resistant to penicillin (penicillin MIC &lt;2 mcg/mL), we transition to <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a> 500 mg orally four times daily. This recommendation applies to treating bacteremic or nonbacteremic pneumococcal pneumonia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For isolates with higher levels of resistance (penicillin MIC ≥2 mcg/mL), we use a respiratory fluoroquinolone (eg, <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> 750 mg orally daily or <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a> 400 mg orally daily).</p><p></p><p>If the organism is susceptible to <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>, a macrolide, or <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a>, and one of these drugs has been used for initial therapy with a good response, it can also be continued orally after completion of IV therapy. If adjunctive macrolide therapy was given at the start of therapy, we generally stop the macrolide when the patient is ready to transition to oral therapy.</p><p>In general, we do not lengthen the course of IV therapy nor the length of hospitalization for patients with pneumococcal pneumonia if bacteremia is documented. One cohort study evaluating 125 patients with bacteremic pneumococcal pneumonia and &gt;1800 patients with nonbacteremic CAP found no difference in outcomes between the two groups [<a href="#rid129">129</a>]. In another small study evaluating patients with bacteremia pneumococcal pneumonia, no clinical failures occurred when patients were transitioned to oral therapy upon reaching clinical stability [<a href="#rid130">130</a>].</p><p class="headingAnchor" id="H776682657"><span class="h2">Duration of therapy</span><span class="headingEndMark"> — </span>The duration of therapy is based on the patient's clinical response to therapy and presence of complications.</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with pneumococcal pneumonia (without bacteremia or other complication), the recommended duration of therapy is five days. Generally, we treat until the patient is clinically stable, afebrile, and showing continued signs of improvement. In the absence of complications, a treatment course longer than seven days is rarely necessary.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with bacteremic pneumococcal pneumonia who are responding to therapy, we treat for seven days, acknowledging that there are limited data to support this approach.</p><p></p><p>Pneumococcal pneumonia that is complicated by meningitis or endocarditis require longer courses of therapy. If empyema or septic arthritis is present, source control and longer courses of therapy are also needed. (See  <a class="medical medical_review" href="/d/html/1290.html" rel="external">"Initial therapy and prognosis of community-acquired bacterial meningitis in adults"</a> and  <a class="medical medical_review" href="/d/html/119384.html" rel="external">"Management and prognosis of parapneumonic pleural effusion and empyema in adults"</a> and  <a class="medical medical_review" href="/d/html/3168.html" rel="external">"Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia in adults"</a>.)</p><p class="headingAnchor" id="H4271795592"><span class="h1">FAILURE TO IMPROVE</span><span class="headingEndMark"> — </span>If a patient with pneumococcal pneumonia has not responded to appropriate antibiotic therapy after three or four days of treatment, a careful search for a complication should be made. The most likely complication is an empyema, although evaluation should also include a search for other complications. (See <a class="local">'Complications'</a> above.)</p><p class="headingAnchor" id="H32"><span class="h1">MORTALITY</span><span class="headingEndMark"> — </span>The mortality rate for pneumococcal pneumonia varies by severity at presentation and host factors and depends greatly on whether one is considering 7-day, 30-day, 90-day, or long-term survival. In patients who are hospitalized for bacteremic pneumococcal pneumonia, in-hospital mortality is about 12 to 15 percent and 90-day mortality is about 25 to 30 percent. In each case, the mortality is approximately 50 percent lower for patients with nonbacteremic pneumococcal pneumonia [<a href="#rid15">15,16,70,126</a>].</p><p>A prospective observational study of 638 patients with pneumococcal pneumonia identified the following features of the pneumonia associated with mortality by multivariate analysis [<a href="#rid131">131</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Shock – HR 5.8, 95% CI 3.4-9.8</p><p class="bulletIndent1"><span class="glyph">●</span>Need for mechanical ventilation – OR 4.4</p><p class="bulletIndent1">Bilateral disease – Hazard ratio (HR) 2.0, 95% CI 1.2-3.2</p><p class="bulletIndent1"><span class="glyph">●</span>Suspected aspiration – HR 2.8, 95% CI 1.6-5.0</p><p class="bulletIndent1"><span class="glyph">●</span>HIV infection – HR 2.1, 95% CI 1.1-3.8</p><p class="bulletIndent1"><span class="glyph">●</span>Renal failure – HR 1.9, 95% CI 1.1-3.1</p><p class="bulletIndent1"><span class="glyph">●</span>Pneumonia severity index – HR for class IV versus classes I to III: 2.6, 95% CI 1.3-5.4; for class V versus I to III: 3.2, 95% CI 1.5-6.9 (see  <a class="medical medical_review" href="/d/html/7016.html" rel="external">"Morbidity and mortality associated with community-acquired pneumonia in adults", section on 'Pneumonia severity index'</a>)</p><p></p><p>Comorbid conditions are a significant predictor of poor outcome in bacteremic pneumococcal disease. This was illustrated in a multicenter five-country study of 460 such patients (82 percent with pneumonia). Among those who died, about half of deaths were attributable to worsening of a pre-existing condition [<a href="#rid132">132</a>]. Additional factors independently associated with mortality in a second large observational study included:</p><p class="bulletIndent1"><span class="glyph">●</span>Age &gt;65 years – Odds ratio (OR) 2.2</p><p class="bulletIndent1"><span class="glyph">●</span>Residence in a nursing home – OR 2.8</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of chronic lung disease – OR 2.5</p><p class="bulletIndent1"><span class="glyph">●</span>High acute physiology and chronic health – For scores of 9 to 14, OR 7.6; for scores 15 to 17, OR 22; for scores &gt;17, OR 41</p><p></p><p>Similarly, a study of predictors of mortality among United States veterans with pneumococcal infections identified dialysis during hospitalization, moderate to severe liver disease, Parkinson disease, multiple sclerosis, dementia, and fluid and electrolyte disorders [<a href="#rid133">133</a>].</p><p>It is important for practitioners to explain to their patients that the recovery from pneumococcal pneumonia may be slow. In many patients, especially those who are older adults and for reasons that are unknown, it may take weeks to months before they feel as if they have returned to their previous state of health. For those who survive 90 days, mortality when compared with age-matched persons who have not had pneumococcal pneumonia remains excessive for decades [<a href="#rid21">21,88</a>]. In fact, life expectancy may be shortened by 10 years. While pneumonia may simply be a marker for persons at risk of dying, some studies suggest that long-lasting epigenetic changes may be responsible [<a href="#rid134">134</a>], a concept supported by the finding that the detrimental effect on survival is proportional to the severity of the pneumonia.</p><p>The risk of overwhelming bacteremia, septic shock, and death is greatly increased in splenectomized patients since, in the absence of anticapsular antibody, the spleen is the principal site for clearance of this bacterium from the bloodstream. (See  <a class="medical medical_review" href="/d/html/1404.html" rel="external">"Clinical features, evaluation, and management of fever in patients with impaired splenic function"</a>.)</p><p class="headingAnchor" id="H1231043106"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>The most effective means of prevention is pneumococcal vaccination (see  <a class="medical medical_review" href="/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults"</a>). This severe risk also applies to patients with sickle cell disease.</p><p>The risk of developing pneumococcal pneumonia can be reduced by avoiding behaviors that are associated with the disease (eg, excess alcohol ingestion or cigarette smoking) and by controlling conditions (eg, diabetes mellitus) that increase risk.</p><p class="headingAnchor" id="H350692899"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/104226.html" rel="external">"Society guideline links: Community-acquired pneumonia in adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/110422.html" rel="external">"Society guideline links: Pneumococcal vaccination in adults"</a>.)</p><p class="headingAnchor" id="H33"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/4002.html" rel="external">"Patient education: Pneumonia in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H34"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Background</strong> – <em>Streptococcus pneumoniae </em>(pneumococcus) is the most commonly identified bacterial cause of community-acquired pneumonia (CAP), accounting for 10 to 25 percent of cases in the United States and a higher percentage in Europe and developing countries. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – Risk factors for acquisition include extremes of age, crowded living conditions, cigarette smoking, alcohol use disorders, and certain races or ethnicities (ie, Black Americans and Native Americans). Antecedent viral infection, particularly with influenza, also predisposes to pneumococcal pneumonia. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transmission</strong> – Transmission of pneumococcus occurs from person to person by intimate contact or aerosol. Following transmission, pneumococci colonize the nasopharynx. Colonization is an active process in which bacterial antigen is incorporated by dendritic cells and is processed leading to antibody production. Pneumonia develops if nasopharyngeal secretions are carried into the lungs (called aspiration) and are not cleared rapidly and effectively before antibody has been produced.(See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – The "classic syndrome" associated with pneumococcal pneumonia is abrupt onset fever, chills, cough, and pleuritic chest pain. This description is derived from the preantibiotic era when pneumococcal pneumonia affected young adults with robust immune responses. Today, older adults are primarily affected, illness onset is more gradual, and respiratory symptoms may be less pronounced. Findings on physical examination and chest imaging are similar to other forms of CAP. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Definitive diagnosis of pneumococcal pneumonia requires culture of pneumococcus from a normally sterile site (eg, blood or pleural fluid). However, detection of pneumococcus in sputum by Gram stain or culture and/or a positive urine pneumococcal antigen test is generally sufficient to make a presumptive diagnosis and direct therapy. (See <a class="local">'Approach to diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preferred treatment</strong> – For most patients hospitalized with pneumococcal pneumonia (with or without bacteremia), we suggest <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> (1 g intravenously [IV] every 24 hours) over other beta-lactams (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Ceftriaxone is preferred because of its once-daily dosing and because ceftriaxone achieves drug levels sufficient to treat most pneumococcal isolates in the United States. Modifications to this approach may be needed for patients who cannot tolerate cephalosporins, when there is concern for ceftriaxone resistance (minimum inhibitory concentration [MIC] &gt;2 mcg/mL), or for complications such as meningitis or empyema. (See <a class="local">'Directed therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cephalosporin resistance or intolerance</strong> – For patients with pneumococcal pneumonia who cannot tolerate a third-generation cephalosporin or when <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> resistance is a concern, we typically treat with a respiratory fluoroquinolone (ie, <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a> 750 mg daily or <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a> 400 mg daily) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Susceptibility to fluoroquinolones remains high and is generally stable across regions. Additional options are discussed above. (See <a class="local">'Directed therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunctive treatments</strong> – To help quell the profound inflammatory response that can occur with pneumococcal pneumonia, some experts add a macrolide (ie, <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>) to <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> in patients for the first few days of therapy (see <a class="local">'Adjunctive macrolide therapy'</a> above). For similar reasons, in selected patients with severe pneumonia and marked systemic inflammation (eg, septic shock), giving adjunctive glucocorticoids may be reasonable. (See <a class="local">'Adjunctive glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transition to oral therapy</strong> – For all hospitalized patients, we treat initially with IV antibiotic therapy. We transition to an oral antibiotic once the patient is stable, improving, and able to tolerate oral therapy. For penicillin-susceptible strains we transition to <a class="drug drug_general" data-topicid="8673" href="/d/drug information/8673.html" rel="external">amoxicillin</a>; for strains with reduced susceptibility to penicillin (MIC ≥2 mcg/mL), we transition to a respiratory fluoroquinolone (eg, <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a>, <a class="drug drug_general" data-topicid="10311" href="/d/drug information/10311.html" rel="external">moxifloxacin</a>). (See <a class="local">'Transition to oral therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of therapy</strong> – Duration of therapy is usually five days. Our approach is similar for patients with bacteremic pneumonia, although we treat for seven days. (See <a class="local">'Duration of therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – Patients who do not improve within a few days of appropriate antibiotic therapy should be evaluated for complications. Empyema is the most common complication, though endocarditis, pericarditis, and septic arthritis also occur. Meningitis can also complicate pneumonia, though this is typically apparent at presentation. (See <a class="local">'Failure to improve'</a> above and <a class="local">'Complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mortality</strong> – In-hospital mortality from pneumococcal pneumonia is approximately 7 to 15 percent. Patients with severe infection, chronic illnesses (eg diabetes, heart failure), impaired antibody responses (eg, AIDS, multiple myeloma) or impaired splenic function are at higher risk for poor outcomes. (See <a class="local">'Mortality'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention</strong> – The most effective means of prevention is pneumococcal vaccination. Risk can also be reduced by avoiding conditions that are associated with the disease (eg, excess alcohol ingestion or cigarette smoking) and by controlling conditions that are associated (eg, diabetes mellitus). (See <a class="local">'Prevention'</a> above.)</p><p></p><p class="headingAnchor" id="H83505650"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Thomas J Marrie, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Heffron R. Symptoms of lobar pneumonia in Pneumonia with special reference to pneumococcus lobar pneumonia, Harvard University Press, Cambridge 1939. p.501.</li><li><a class="nounderline abstract_t">Jain S, Self WH, Wunderink RG, et al. Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med 2015; 373:415.</a></li><li><a class="nounderline abstract_t">Musher DM, Roig IL, Cazares G, et al. Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study. J Infect 2013; 67:11.</a></li><li><a class="nounderline abstract_t">Restrepo MI, Mortensen EM, Velez JA, et al. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest 2008; 133:610.</a></li><li><a class="nounderline abstract_t">Gadsby NJ, Russell CD, McHugh MP, et al. Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia. Clin Infect Dis 2016; 62:817.</a></li><li><a class="nounderline abstract_t">Musher DM, Jesudasen SS, Barwatt JW, et al. Normal Respiratory Flora as a Cause of Community-Acquired Pneumonia. Open Forum Infect Dis 2020; 7:ofaa307.</a></li><li><a class="nounderline abstract_t">Musher DM, Abers MS, Bartlett JG. Evolving Understanding of the Causes of Pneumonia in Adults, With Special Attention to the Role of Pneumococcus. Clin Infect Dis 2017; 65:1736.</a></li><li><a class="nounderline abstract_t">File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010; 51:1395.</a></li><li><a class="nounderline abstract_t">Bjarnason A, Westin J, Lindh M, et al. Incidence, Etiology, and Outcomes of Community-Acquired Pneumonia: A Population-Based Study. Open Forum Infect Dis 2018; 5:ofy010.</a></li><li><a class="nounderline abstract_t">Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372:1114.</a></li><li><a class="nounderline abstract_t">Para RA, Fomda BA, Jan RA, et al. Microbial etiology in hospitalized North Indian adults with community-acquired pneumonia. Lung India 2018; 35:108.</a></li><li><a class="nounderline abstract_t">Watanakunakorn C, Bailey TA. Adult bacteremic pneumococcal pneumonia in a community teaching hospital, 1992-1996. A detailed analysis of 108 cases. Arch Intern Med 1997; 157:1965.</a></li><li><a class="nounderline abstract_t">Said MA, Johnson HL, Nonyane BA, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS One 2013; 8:e60273.</a></li><li><a class="nounderline abstract_t">Musher DM, Montoya R, Wanahita A. Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2004; 39:165.</a></li><li><a class="nounderline abstract_t">Musher DM, Alexandraki I, Graviss EA, et al. Bacteremic and nonbacteremic pneumococcal pneumonia. A prospective study. Medicine (Baltimore) 2000; 79:210.</a></li><li><a class="nounderline abstract_t">Brandenburg JA, Marrie TJ, Coley CM, et al. Clinical presentation, processes and outcomes of care for patients with pneumococcal pneumonia. J Gen Intern Med 2000; 15:638.</a></li><li><a class="nounderline abstract_t">Ludwig E, Bonanni P, Rohde G, et al. The remaining challenges of pneumococcal disease in adults. Eur Respir Rev 2012; 21:57.</a></li><li><a class="nounderline abstract_t">Krone CL, van de Groep K, Trzciński K, et al. Immunosenescence and pneumococcal disease: an imbalance in host-pathogen interactions. Lancet Respir Med 2014; 2:141.</a></li><li class="breakAll">Heffron R. Pneumonia. In: Pneumonia, with special reference to pneumococcus lobar pneumonia, Commonwealth Fund, New York  p.1939.</li><li><a class="nounderline abstract_t">HODGES RG, MacLEOD CM. Epidemic pneumococcal pneumonia; description of the epidemic. Am J Hyg 1946; 44:183.</a></li><li><a class="nounderline abstract_t">Linkevicius M, Cristea V, Siira L, et al. Outbreak of invasive pneumococcal disease among shipyard workers, Turku, Finland, May to November 2019. Euro Surveill 2019; 24.</a></li><li><a class="nounderline abstract_t">Mercat A, Nguyen J, Dautzenberg B. An outbreak of pneumococcal pneumonia in two men's shelters. Chest 1991; 99:147.</a></li><li><a class="nounderline abstract_t">Hoge CW, Reichler MR, Dominguez EA, et al. An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail. N Engl J Med 1994; 331:643.</a></li><li><a class="nounderline abstract_t">Gleich S, Morad Y, Echague R, et al. Streptococcus pneumoniae serotype 4 outbreak in a home for the aged: report and review of recent outbreaks. Infect Control Hosp Epidemiol 2000; 21:711.</a></li><li><a class="nounderline abstract_t">Kupronis BA, Richards CL, Whitney CG, Active Bacterial Core Surveillance Team. Invasive pneumococcal disease in older adults residing in long-term care facilities and in the community. J Am Geriatr Soc 2003; 51:1520.</a></li><li><a class="nounderline abstract_t">Watt JP, O'Brien KL, Benin AL, et al. Risk factors for invasive pneumococcal disease among Navajo adults. Am J Epidemiol 2007; 166:1080.</a></li><li><a class="nounderline abstract_t">Said MA, O'Brien KL, Nuorti JP, et al. The epidemiologic evidence underlying recommendations for use of pneumococcal polysaccharide vaccine among American Indian and Alaska Native populations. Vaccine 2011; 29:5355.</a></li><li><a class="nounderline abstract_t">Harrison LH, Dwyer DM, Billmann L, et al. Invasive pneumococcal infection in Baltimore, Md: implications for immunization policy. Arch Intern Med 2000; 160:89.</a></li><li><a class="nounderline abstract_t">Garg S, Jain S, Dawood FS, et al. Pneumonia among adults hospitalized with laboratory-confirmed seasonal influenza virus infection-United States, 2005-2008. BMC Infect Dis 2015; 15:369.</a></li><li><a class="nounderline abstract_t">D'Mello A, Lane JR, Tipper JL, et al. Influenza A virus modulation of Streptococcus pneumoniae infection using ex vivo transcriptomics in a human primary lung epithelial cell model reveals differential host glycoconjugate uptake and metabolism. bioRxiv 2023.</a></li><li><a class="nounderline abstract_t">Rowe HM, Rosch JW. Polymicrobial Interactions Operative during Pathogen Transmission. mBio 2021; 12.</a></li><li><a class="nounderline abstract_t">Bhatty M, Pruett SB, Swiatlo E, Nanduri B. Alcohol abuse and Streptococcus pneumoniae infections: consideration of virulence factors and impaired immune responses. Alcohol 2011; 45:523.</a></li><li><a class="nounderline abstract_t">Greenberg D, Givon-Lavi N, Broides A, et al. The contribution of smoking and exposure to tobacco smoke to Streptococcus pneumoniae and Haemophilus influenzae carriage in children and their mothers. Clin Infect Dis 2006; 42:897.</a></li><li><a class="nounderline abstract_t">Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 2000; 342:681.</a></li><li><a class="nounderline abstract_t">Lee TA, Weaver FM, Weiss KB. Impact of pneumococcal vaccination on pneumonia rates in patients with COPD and asthma. J Gen Intern Med 2007; 22:62.</a></li><li><a class="nounderline abstract_t">Castro-Rodriguez JA, Abarca K, Forno E. Asthma and the Risk of Invasive Pneumococcal Disease: A Meta-analysis. Pediatrics 2020; 145.</a></li><li><a class="nounderline abstract_t">Savage DG, Lindenbaum J, Garrett TJ. Biphasic pattern of bacterial infection in multiple myeloma. Ann Intern Med 1982; 96:47.</a></li><li><a class="nounderline abstract_t">Twomey JJ. Infections complicating multiple myeloma and chronic lymphocytic leukemia. Arch Intern Med 1973; 132:562.</a></li><li><a class="nounderline abstract_t">Nuorti JP, Butler JC, Gelling L, et al. Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California. Ann Intern Med 2000; 132:182.</a></li><li><a class="nounderline abstract_t">Redd SC, Rutherford GW 3rd, Sande MA, et al. The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J Infect Dis 1990; 162:1012.</a></li><li><a class="nounderline abstract_t">Naveau C, Houssiau FA. Pneumococcal sepsis in patients with systemic lupus erythematosus. Lupus 2005; 14:903.</a></li><li><a class="nounderline abstract_t">Kumashi P, Girgawy E, Tarrand JJ, et al. Streptococcus pneumoniae bacteremia in patients with cancer: disease characteristics and outcomes in the era of escalating drug resistance (1998-2002). Medicine (Baltimore) 2005; 84:303.</a></li><li><a class="nounderline abstract_t">Linnemann CC Jr, First MR. Risk of pneumococcal infections in renal transplant patients. JAMA 1979; 241:2619.</a></li><li><a class="nounderline abstract_t">Amber IJ, Gilbert EM, Schiffman G, Jacobson JA. Increased risk of pneumococcal infections in cardiac transplant recipients. Transplantation 1990; 49:122.</a></li><li><a class="nounderline abstract_t">de Bruyn G, Whelan TP, Mulligan MS, et al. Invasive pneumococcal infections in adult lung transplant recipients. Am J Transplant 2004; 4:1366.</a></li><li><a class="nounderline abstract_t">Elias M, Bisharat N, Goldstein LH, et al. Pneumococcal sepsis due to functional hyposplenism in a bone marrow transplant patient. Eur J Clin Microbiol Infect Dis 2004; 23:212.</a></li><li><a class="nounderline abstract_t">Gonzales J, Chakraborty T, Romero M, et al. Streptococcus pneumoniae and Its Virulence Factors H2O2 and Pneumolysin Are Potent Mediators of the Acute Chest Syndrome in Sickle Cell Disease. Toxins (Basel) 2021; 13.</a></li><li><a class="nounderline abstract_t">Wiese AD, Griffin MR, Schaffner W, et al. Opioid Analgesic Use and Risk for Invasive Pneumococcal Diseases: A Nested Case-Control Study. Ann Intern Med 2018; 168:396.</a></li><li><a class="nounderline abstract_t">Wong A, Marrie TJ, Garg S, et al. Welders are at increased risk for invasive pneumococcal disease. Int J Infect Dis 2010; 14:e796.</a></li><li><a class="nounderline abstract_t">Lane JR, Tata M, Briles DE, Orihuela CJ. A Jack of All Trades: The Role of Pneumococcal Surface Protein A in the Pathogenesis of Streptococcus pneumoniae. Front Cell Infect Microbiol 2022; 12:826264.</a></li><li><a class="nounderline abstract_t">Scott NR, Mann B, Tuomanen EI, Orihuela CJ. Multi-Valent Protein Hybrid Pneumococcal Vaccines: A Strategy for the Next Generation of Vaccines. Vaccines (Basel) 2021; 9.</a></li><li><a class="nounderline abstract_t">Bogaert D, De Groot R, Hermans PW. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 2004; 4:144.</a></li><li><a class="nounderline abstract_t">Hussain M, Melegaro A, Pebody RG, et al. A longitudinal household study of Streptococcus pneumoniae nasopharyngeal carriage in a UK setting. Epidemiol Infect 2005; 133:891.</a></li><li><a class="nounderline abstract_t">Musher DM, Groover JE, Reichler MR, et al. Emergence of antibody to capsular polysaccharides of Streptococcus pneumoniae during outbreaks of pneumonia: association with nasopharyngeal colonization. Clin Infect Dis 1997; 24:441.</a></li><li><a class="nounderline abstract_t">Austrian R. Some aspects of the pneumococcal carrier state. J Antimicrob Chemother 1986; 18 Suppl A:35.</a></li><li><a class="nounderline abstract_t">Mandell LA, Niederman MS. Aspiration Pneumonia. N Engl J Med 2019; 380:651.</a></li><li><a class="nounderline abstract_t">Yershov AL, Jordan BS, Guymon CH, Dubick MA. Relationship between the inoculum dose of Streptococcus pneumoniae and pneumonia onset in a rabbit model. Eur Respir J 2005; 25:693.</a></li><li><a class="nounderline abstract_t">Kietzman CC, Gao G, Mann B, et al. Dynamic capsule restructuring by the main pneumococcal autolysin LytA in response to the epithelium. Nat Commun 2016; 7:10859.</a></li><li><a class="nounderline abstract_t">Cundell DR, Gerard NP, Gerard C, et al. Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature 1995; 377:435.</a></li><li><a class="nounderline abstract_t">Domon H, Oda M, Maekawa T, et al. Streptococcus pneumoniae disrupts pulmonary immune defence via elastase release following pneumolysin-dependent neutrophil lysis. Sci Rep 2016; 6:38013.</a></li><li><a class="nounderline abstract_t">Rubins JB, Charboneau D, Paton JC, et al. Dual function of pneumolysin in the early pathogenesis of murine pneumococcal pneumonia. J Clin Invest 1995; 95:142.</a></li><li><a class="nounderline abstract_t">Tuomanen E, Rich R, Zak O. Induction of pulmonary inflammation by components of the pneumococcal cell surface. Am Rev Respir Dis 1987; 135:869.</a></li><li><a class="nounderline abstract_t">Bergeron Y, Ouellet N, Deslauriers AM, et al. Cytokine kinetics and other host factors in response to pneumococcal pulmonary infection in mice. Infect Immun 1998; 66:912.</a></li><li><a class="nounderline abstract_t">Taylor SN, Sanders CV. Unusual manifestations of invasive pneumococcal infection. Am J Med 1999; 107:12S.</a></li><li><a class="nounderline abstract_t">Pande A, Nasir S, Rueda AM, et al. The incidence of necrotizing changes in adults with pneumococcal pneumonia. Clin Infect Dis 2012; 54:10.</a></li><li><a class="nounderline abstract_t">Marrie TJ, Low DE, De Carolis E, Canadian Community-Acquired Pneumonia Investigators. A comparison of bacteremic pneumococcal pneumonia with nonbacteremic community-acquired pneumonia of any etiology--results from a Canadian multicentre study. Can Respir J 2003; 10:368.</a></li><li><a class="nounderline abstract_t">Murphy TF, Fine BC. Bacteremic pneumococcal pneumonia in the elderly. Am J Med Sci 1984; 288:114.</a></li><li><a class="nounderline abstract_t">Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37:230.</a></li><li><a class="nounderline abstract_t">WITT RL, HAMBURGER M. THE NATURE AND TREATMENT OF PNEUMOCOCCAL PNEUMONIA. Med Clin North Am 1963; 47:1257.</a></li><li><a class="nounderline abstract_t">Bordon JM, Fernandez-Botran R, Wiemken TL, et al. Bacteremic pneumococcal pneumonia: clinical outcomes and preliminary results of inflammatory response. Infection 2015; 43:729.</a></li><li><a class="nounderline abstract_t">Metlay JP, Kapoor WN, Fine MJ. Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA 1997; 278:1440.</a></li><li><a class="nounderline abstract_t">Wipf JE, Lipsky BA, Hirschmann JV, et al. Diagnosing pneumonia by physical examination: relevant or relic? Arch Intern Med 1999; 159:1082.</a></li><li><a class="nounderline abstract_t">Gardner JG, Bhamidipati DR, Rueda AM, et al. White Blood Cell Counts, Alcoholism, and Cirrhosis in Pneumococcal Pneumonia. Open Forum Infect Dis 2017; 4:ofx034.</a></li><li><a class="nounderline abstract_t">Ort S, Ryan JL, Barden G, D'Esopo N. Pneumococcal pneumonia in hospitalized patients. Clinical and radiological presentations. JAMA 1983; 249:214.</a></li><li><a class="nounderline abstract_t">Yangco BG, Deresinski SC. Necrotizing or cavitating pneumonia due to Streptococcus Pneumoniae: report of four cases and review of the literature. Medicine (Baltimore) 1980; 59:449.</a></li><li><a class="nounderline abstract_t">Light RW, Girard WM, Jenkinson SG, George RB. Parapneumonic effusions. Am J Med 1980; 69:507.</a></li><li><a class="nounderline abstract_t">Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis 2007; 45:158.</a></li><li><a class="nounderline abstract_t">Violi F, Cangemi R, Falcone M, et al. Cardiovascular Complications and Short-term Mortality Risk in Community-Acquired Pneumonia. Clin Infect Dis 2017; 64:1486.</a></li><li><a class="nounderline abstract_t">Wiese AD, Mitchel E, Ndi D, et al. Risk of Acute Myocardial Infarction Among Patients With Laboratory-Confirmed Invasive Pneumococcal Disease: A Self-Controlled Case Series Study. Clin Infect Dis 2023; 76:2171.</a></li><li><a class="nounderline abstract_t">Corrales-Medina VF, Musher DM, Wells GA, et al. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation 2012; 125:773.</a></li><li><a class="nounderline abstract_t">Viasus D, Garcia-Vidal C, Manresa F, et al. Risk stratification and prognosis of acute cardiac events in hospitalized adults with community-acquired pneumonia. J Infect 2013; 66:27.</a></li><li><a class="nounderline abstract_t">Corrales-Medina VF, Fatemi O, Serpa J, et al. The association between Staphylococcus aureus bacteremia and acute myocardial infarction. Scand J Infect Dis 2009; 41:511.</a></li><li><a class="nounderline abstract_t">Kwong JC, Schwartz KL, Campitelli MA. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med 2018; 378:2540.</a></li><li><a class="nounderline abstract_t">Musher DM, Abers MS, Corrales-Medina VF. Acute Infection and Myocardial Infarction. N Engl J Med 2019; 380:171.</a></li><li><a class="nounderline abstract_t">Reyes LF, Restrepo MI, Hinojosa CA, et al. Severe Pneumococcal Pneumonia Causes Acute Cardiac Toxicity and Subsequent Cardiac Remodeling. Am J Respir Crit Care Med 2017; 196:609.</a></li><li><a class="nounderline abstract_t">Guiraud V, Amor MB, Mas JL, Touzé E. Triggers of ischemic stroke: a systematic review. Stroke 2010; 41:2669.</a></li><li><a class="nounderline abstract_t">Elkind MS, Carty CL, O'Meara ES, et al. Hospitalization for infection and risk of acute ischemic stroke: the Cardiovascular Health Study. Stroke 2011; 42:1851.</a></li><li><a class="nounderline abstract_t">Sandvall B, Rueda AM, Musher DM. Long-term survival following pneumococcal pneumonia. Clin Infect Dis 2013; 56:1145.</a></li><li><a class="nounderline abstract_t">DiNardo AR, Netea MG, Musher DM. Postinfectious Epigenetic Immune Modifications - A Double-Edged Sword. N Engl J Med 2021; 384:261.</a></li><li><a class="nounderline abstract_t">Moore MA, Merson MH, Charache P, Shepard RH. The characteristics and mortality of outpatient-acquired pneumonia. Johns Hopkins Med J 1977; 140:9.</a></li><li><a class="nounderline abstract_t">Madison JM, Irwin RS. Expectorated sputum for community-acquired pneumonia: a sacred cow. Arch Intern Med 2004; 164:1725.</a></li><li><a class="nounderline abstract_t">García-Vázquez E, Marcos MA, Mensa J, et al. Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. Arch Intern Med 2004; 164:1807.</a></li><li><a class="nounderline abstract_t">Ogawa H, Kitsios GD, Iwata M, Terasawa T. Sputum Gram Stain for Bacterial Pathogen Diagnosis in Community-acquired Pneumonia: A Systematic Review and Bayesian Meta-analysis of Diagnostic Accuracy and Yield. Clin Infect Dis 2020; 71:499.</a></li><li><a class="nounderline abstract_t">Gutiérrez F, Masiá M, Rodríguez JC, et al. Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin Infect Dis 2003; 36:286.</a></li><li><a class="nounderline abstract_t">Boulware DR, Daley CL, Merrifield C, et al. Rapid diagnosis of pneumococcal pneumonia among HIV-infected adults with urine antigen detection. J Infect 2007; 55:300.</a></li><li><a class="nounderline abstract_t">Neuman MI, Harper MB. Evaluation of a rapid urine antigen assay for the detection of invasive pneumococcal disease in children. Pediatrics 2003; 112:1279.</a></li><li><a class="nounderline abstract_t">Esposito S, Bosis S, Colombo R, et al. Evaluation of rapid assay for detection of Streptococcus pneumoniae urinary antigen among infants and young children with possible invasive pneumococcal disease. Pediatr Infect Dis J 2004; 23:365.</a></li><li><a class="nounderline abstract_t">Sherwin RL, Gray S, Alexander R, et al. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia. J Infect Dis 2013; 208:1813.</a></li><li><a class="nounderline abstract_t">Pride MW, Huijts SM, Wu K, et al. Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine. Clin Vaccine Immunol 2012; 19:1131.</a></li><li><a class="nounderline abstract_t">Wunderink RG, Self WH, Anderson EJ, et al. Pneumococcal Community-Acquired Pneumonia Detected by Serotype-Specific Urinary Antigen Detection Assays. Clin Infect Dis 2018; 66:1504.</a></li><li><a class="nounderline abstract_t">Gadsby NJ, McHugh MP, Forbes C, et al. Comparison of Unyvero P55 Pneumonia Cartridge, in-house PCR and culture for the identification of respiratory pathogens and antibiotic resistance in bronchoalveolar lavage fluids in the critical care setting. Eur J Clin Microbiol Infect Dis 2019; 38:1171.</a></li><li><a class="nounderline abstract_t">Buchan BW, Windham S, Balada-Llasat JM, et al. Practical Comparison of the BioFire FilmArray Pneumonia Panel to Routine Diagnostic Methods and Potential Impact on Antimicrobial Stewardship in Adult Hospitalized Patients with Lower Respiratory Tract Infections. J Clin Microbiol 2020; 58.</a></li><li><a class="nounderline abstract_t">Murphy CN, Fowler R, Balada-Llasat JM, et al. Multicenter Evaluation of the BioFire FilmArray Pneumonia/Pneumonia Plus Panel for Detection and Quantification of Agents of Lower Respiratory Tract Infection. J Clin Microbiol 2020; 58.</a></li><li class="breakAll">Unpublished data from the author.</li><li><a class="nounderline abstract_t">Lim WS, Macfarlane JT, Boswell TC, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001; 56:296.</a></li><li><a class="nounderline abstract_t">Musher DM, Mediwala R, Phan HM, et al. Nonspecificity of assaying for IgG antibody to pneumolysin in circulating immune complexes as a means to diagnose pneumococcal pneumonia. Clin Infect Dis 2001; 32:534.</a></li><li><a class="nounderline abstract_t">Albrich WC, Madhi SA, Adrian PV, et al. Genomic load from sputum samples and nasopharyngeal swabs for diagnosis of pneumococcal pneumonia in HIV-infected adults. J Clin Microbiol 2014; 52:4224.</a></li><li><a class="nounderline abstract_t">Messaoudi M, Milenkov M, Albrich WC, et al. The Relevance of a Novel Quantitative Assay to Detect up to 40 Major Streptococcus pneumoniae Serotypes Directly in Clinical Nasopharyngeal and Blood Specimens. PLoS One 2016; 11:e0151428.</a></li><li><a class="nounderline abstract_t">Musher DM. Editorial Commentary: Quantitative Molecular Approach to Diagnosing Pneumonia. Clin Infect Dis 2016; 62:824.</a></li><li><a class="nounderline abstract_t">Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200:e45.</a></li><li class="breakAll">United States Centers for Disease Control and Prevention. ABCs Report: Streptococcus pneumoniae, 2018. https://www.cdc.gov/abcs/reports-findings/survreports/spneu18.html (Accessed on November 23, 2020).</li><li><a class="nounderline abstract_t">Pfaller MA, Mendes RE, Duncan LR, et al. In Vitro Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016). Antimicrob Agents Chemother 2018; 62.</a></li><li><a class="nounderline abstract_t">Mendes RE, Farrell DJ, Flamm RK, et al. In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States. Antimicrob Agents Chemother 2016; 60:4407.</a></li><li><a class="nounderline abstract_t">File TM Jr, Low DE, Eckburg PB, et al. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 2011; 66 Suppl 3:iii19.</a></li><li><a class="nounderline abstract_t">Alexander E, Goldberg L, Das AF, et al. Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial. JAMA 2019; 322:1661.</a></li><li><a class="nounderline abstract_t">File TM, Goldberg L, Das A, et al. Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial. Clin Infect Dis 2019; 69:1856.</a></li><li><a class="nounderline abstract_t">Jones RN, Schuchert JE, Mendes RE. Dalbavancin Activity When Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011 to 2014). Antimicrob Agents Chemother 2016; 60:3419.</a></li><li><a class="nounderline abstract_t">Morrissey I, Hawser S, Lob SH, et al. In Vitro Activity of Eravacycline against Gram-Positive Bacteria Isolated in Clinical Laboratories Worldwide from 2013 to 2017. Antimicrob Agents Chemother 2020; 64.</a></li><li><a class="nounderline abstract_t">Pfaller MA, Rhomberg PR, Huband MD, Flamm RK. Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014). Diagn Microbiol Infect Dis 2018; 90:143.</a></li><li><a class="nounderline abstract_t">Zhang YQ, Zou SL, Zhao H, et al. Ceftriaxone combination therapy versus respiratory fluoroquinolone monotherapy for community-acquired pneumonia: A meta-analysis. Am J Emerg Med 2018; 36:1759.</a></li><li><a class="nounderline abstract_t">Chaudhry SB, Veve MP, Wagner JL. Cephalosporins: A Focus on Side Chains and β-Lactam Cross-Reactivity. Pharmacy (Basel) 2019; 7.</a></li><li><a class="nounderline abstract_t">D'Errico S, Frati P, Zanon M, et al. Cephalosporins' Cross-Reactivity and the High Degree of Required Knowledge. Case Report and Review of the Literature. Antibiotics (Basel) 2020; 9.</a></li><li><a class="nounderline abstract_t">Lin E, Stanek RJ, Mufson MA. Lack of synergy of erythromycin combined with penicillin or cefotaxime against Streptococcus pneumoniae in vitro. Antimicrob Agents Chemother 2003; 47:1151.</a></li><li><a class="nounderline abstract_t">Corrales-Medina VF, Musher DM. Immunomodulatory agents in the treatment of community-acquired pneumonia: a systematic review. J Infect 2011; 63:187.</a></li><li><a class="nounderline abstract_t">Martínez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36:389.</a></li><li><a class="nounderline abstract_t">Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170:440.</a></li><li><a class="nounderline abstract_t">Mufson MA, Stanek RJ. Revisiting combination antibiotic therapy for community-acquired invasive Streptococcus pneumoniae pneumonia. Clin Infect Dis 2006; 42:304.</a></li><li><a class="nounderline abstract_t">Arnold FW, Lopardo G, Wiemken TL, et al. Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia. Respir Med 2018; 140:115.</a></li><li><a class="nounderline abstract_t">Bordón J, Peyrani P, Brock GN, et al. The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort study. Chest 2008; 133:618.</a></li><li><a class="nounderline abstract_t">Ramirez JA, Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia. Arch Intern Med 2001; 161:848.</a></li><li><a class="nounderline abstract_t">Aspa J, Rajas O, Rodriguez de Castro F, et al. Impact of initial antibiotic choice on mortality from pneumococcal pneumonia. Eur Respir J 2006; 27:1010.</a></li><li><a class="nounderline abstract_t">Kalin M, Ortqvist A, Almela M, et al. Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries. J Infect Dis 2000; 182:840.</a></li><li><a class="nounderline abstract_t">Morton JB, Morrill HJ, LaPlante KL, Caffrey AR. Predictors of Mortality Among U.S. Veterans With Streptococcus Pneumoniae Infections. Am J Prev Med 2016.</a></li><li><a class="nounderline abstract_t">DiNardo AR, Rajapakshe K, Nishiguchi T, et al. DNA hypermethylation during tuberculosis dampens host immune responsiveness. J Clin Invest 2020; 130:3113.</a></li></ol></div><div id="topicVersionRevision">Topic 7013 Version 33.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Heffron R. Symptoms of lobar pneumonia in Pneumonia with special reference to pneumococcus lobar pneumonia, Harvard University Press, Cambridge 1939. p.501.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26172429" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23523447" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17989157" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26747825" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32968689" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Normal Respiratory Flora as a Cause of Community-Acquired Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29028977" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Evolving Understanding of the Causes of Pneumonia in Adults, With Special Attention to the Role of Pneumococcus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21067350" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29479548" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Incidence, Etiology, and Outcomes of Community-Acquired Pneumonia: A Population-Based Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25785969" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29487244" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Microbial etiology in hospitalized North Indian adults with community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9308508" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Adult bacteremic pneumococcal pneumonia in a community teaching hospital, 1992-1996. A detailed analysis of 108 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23565216" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15307023" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10941350" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Bacteremic and nonbacteremic pneumococcal pneumonia. A prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11029678" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clinical presentation, processes and outcomes of care for patients with pneumococcal pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22379175" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The remaining challenges of pneumococcal disease in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24503269" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Immunosenescence and pneumococcal disease: an imbalance in host-pathogen interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24503269" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Immunosenescence and pneumococcal disease: an imbalance in host-pathogen interactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21003015" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Epidemic pneumococcal pneumonia; description of the epidemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31822326" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Outbreak of invasive pneumococcal disease among shipyard workers, Turku, Finland, May to November 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1984946" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : An outbreak of pneumococcal pneumonia in two men's shelters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8052273" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11089655" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Streptococcus pneumoniae serotype 4 outbreak in a home for the aged: report and review of recent outbreaks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14687379" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Invasive pneumococcal disease in older adults residing in long-term care facilities and in the community.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17693393" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Risk factors for invasive pneumococcal disease among Navajo adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21664217" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The epidemiologic evidence underlying recommendations for use of pneumococcal polysaccharide vaccine among American Indian and Alaska Native populations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10632309" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Invasive pneumococcal infection in Baltimore, Md: implications for immunization policy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26307108" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Pneumonia among adults hospitalized with laboratory-confirmed seasonal influenza virus infection-United States, 2005-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36778321" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Influenza A virus modulation of Streptococcus pneumoniae infection using ex vivo transcriptomics in a human primary lung epithelial cell model reveals differential host glycoconjugate uptake and metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34006664" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Polymicrobial Interactions Operative during Pathogen Transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21827928" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Alcohol abuse and Streptococcus pneumoniae infections: consideration of virulence factors and impaired immune responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16511750" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The contribution of smoking and exposure to tobacco smoke to Streptococcus pneumoniae and Haemophilus influenzae carriage in children and their mothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10706897" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17351841" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Impact of pneumococcal vaccination on pneumonia rates in patients with COPD and asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31843863" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Asthma and the Risk of Invasive Pneumococcal Disease: A Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6976144" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Biphasic pattern of bacterial infection in multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4542660" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Infections complicating multiple myeloma and chronic lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10651598" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Epidemiologic relation between HIV and invasive pneumococcal disease in San Francisco County, California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2230229" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16335583" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pneumococcal sepsis in patients with systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16148730" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Streptococcus pneumoniae bacteremia in patients with cancer: disease characteristics and outcomes in the era of escalating drug resistance (1998-2002).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/374767" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Risk of pneumococcal infections in renal transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2301002" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Increased risk of pneumococcal infections in cardiac transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15268742" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Invasive pneumococcal infections in adult lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14986163" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Pneumococcal sepsis due to functional hyposplenism in a bone marrow transplant patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33671422" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Streptococcus pneumoniae and Its Virulence Factors H2O2 and Pneumolysin Are Potent Mediators of the Acute Chest Syndrome in Sickle Cell Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29435555" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Opioid Analgesic Use and Risk for Invasive Pneumococcal Diseases: A Nested Case-Control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20637673" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Welders are at increased risk for invasive pneumococcal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35186799" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : A Jack of All Trades: The Role of Pneumococcal Surface Protein A in the Pathogenesis of Streptococcus pneumoniae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33801372" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Multi-Valent Protein Hybrid Pneumococcal Vaccines: A Strategy for the Next Generation of Vaccines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14998500" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Streptococcus pneumoniae colonisation: the key to pneumococcal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16181510" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : A longitudinal household study of Streptococcus pneumoniae nasopharyngeal carriage in a UK setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9114197" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Emergence of antibody to capsular polysaccharides of Streptococcus pneumoniae during outbreaks of pneumonia: association with nasopharyngeal colonization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3745031" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Some aspects of the pneumococcal carrier state.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30763196" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Aspiration Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15802345" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Relationship between the inoculum dose of Streptococcus pneumoniae and pneumonia onset in a rabbit model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26924467" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Dynamic capsule restructuring by the main pneumococcal autolysin LytA in response to the epithelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7566121" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27892542" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Streptococcus pneumoniae disrupts pulmonary immune defence via elastase release following pneumolysin-dependent neutrophil lysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7814608" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Dual function of pneumolysin in the early pathogenesis of murine pneumococcal pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3565933" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Induction of pulmonary inflammation by components of the pneumococcal cell surface.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9488375" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Cytokine kinetics and other host factors in response to pneumococcal pulmonary infection in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10451005" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Unusual manifestations of invasive pneumococcal infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22042878" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The incidence of necrotizing changes in adults with pneumococcal pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14571288" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : A comparison of bacteremic pneumococcal pneumonia with nonbacteremic community-acquired pneumonia of any etiology--results from a Canadian multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6486161" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Bacteremic pneumococcal pneumonia in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12856216" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14062092" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : THE NATURE AND TREATMENT OF PNEUMOCOCCAL PNEUMONIA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26424683" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Bacteremic pneumococcal pneumonia: clinical outcomes and preliminary results of inflammatory response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9356004" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Does this patient have community-acquired pneumonia? Diagnosing pneumonia by history and physical examination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10335685" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Diagnosing pneumonia by physical examination: relevant or relic?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28730156" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : White Blood Cell Counts, Alcoholism, and Cirrhosis in Pneumococcal Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6848806" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Pneumococcal pneumonia in hospitalized patients. Clinical and radiological presentations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7442531" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Necrotizing or cavitating pneumonia due to Streptococcus Pneumoniae: report of four cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7424940" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Parapneumonic effusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17578773" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The association between pneumococcal pneumonia and acute cardiac events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28205683" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Cardiovascular Complications and Short-term Mortality Risk in Community-Acquired Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36751004" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Risk of Acute Myocardial Infarction Among Patients With Laboratory-Confirmed Invasive Pneumococcal Disease: A Self-Controlled Case Series Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22219349" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22981899" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Risk stratification and prognosis of acute cardiac events in hospitalized adults with community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19396667" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The association between Staphylococcus aureus bacteremia and acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29949484" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30625066" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Acute Infection and Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28614669" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Severe Pneumococcal Pneumonia Causes Acute Cardiac Toxicity and Subsequent Cardiac Remodeling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20947837" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Triggers of ischemic stroke: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21546476" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Hospitalization for infection and risk of acute ischemic stroke: the Cardiovascular Health Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23300240" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Long-term survival following pneumococcal pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33471978" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Postinfectious Epigenetic Immune Modifications - A Double-Edged Sword.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/836513" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The characteristics and mortality of outpatient-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15364664" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Expectorated sputum for community-acquired pneumonia: a sacred cow.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15364677" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31504334" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Sputum Gram Stain for Bacterial Pathogen Diagnosis in Community-acquired Pneumonia: A Systematic Review and Bayesian Meta-analysis of Diagnostic Accuracy and Yield.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12539069" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17692384" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Rapid diagnosis of pneumococcal pneumonia among HIV-infected adults with urine antigen detection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14654597" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Evaluation of a rapid urine antigen assay for the detection of invasive pneumococcal disease in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15071298" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Evaluation of rapid assay for detection of Streptococcus pneumoniae urinary antigen among infants and young children with possible invasive pneumococcal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24092845" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged≥50 years with community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22675155" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Validation of an immunodiagnostic assay for detection of 13 Streptococcus pneumoniae serotype-specific polysaccharides in human urine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29342250" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Pneumococcal Community-Acquired Pneumonia Detected by Serotype-Specific Urinary Antigen Detection Assays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30859358" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Comparison of Unyvero P55 Pneumonia Cartridge, in-house PCR and culture for the identification of respiratory pathogens and antibiotic resistance in bronchoalveolar lavage fluids in the critical care setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32350045" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Practical Comparison of the BioFire FilmArray Pneumonia Panel to Routine Diagnostic Methods and Potential Impact on Antimicrobial Stewardship in Adult Hospitalized Patients with Lower Respiratory Tract Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32350043" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Multicenter Evaluation of the BioFire FilmArray Pneumonia/Pneumonia Plus Panel for Detection and Quantification of Agents of Lower Respiratory Tract Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32350043" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Multicenter Evaluation of the BioFire FilmArray Pneumonia/Pneumonia Plus Panel for Detection and Quantification of Agents of Lower Respiratory Tract Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11254821" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11181114" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Nonspecificity of assaying for IgG antibody to pneumolysin in circulating immune complexes as a means to diagnose pneumococcal pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25253798" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Genomic load from sputum samples and nasopharyngeal swabs for diagnosis of pneumococcal pneumonia in HIV-infected adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26986831" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : The Relevance of a Novel Quantitative Assay to Detect up to 40 Major Streptococcus pneumoniae Serotypes Directly in Clinical Nasopharyngeal and Blood Specimens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26747824" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Editorial Commentary: Quantitative Molecular Approach to Diagnosing Pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31573350" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31573350" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29158271" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : In Vitro Activities of Ceftaroline and Comparators against Streptococcus pneumoniae Isolates from U.S. Hospitals: Results from Seven Years of the AWARE Surveillance Program (2010 to 2016).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27161634" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : In Vitro Activity of Lefamulin Tested against Streptococcus pneumoniae with Defined Serotypes, Including Multidrug-Resistant Isolates Causing Lower Respiratory Tract Infections in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21482566" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31560372" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30722059" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27001811" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Dalbavancin Activity When Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011 to 2014).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31843997" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : In Vitro Activity of Eravacycline against Gram-Positive Bacteria Isolated in Clinical Laboratories Worldwide from 2013 to 2017.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29157954" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Activity of omadacycline tested against Streptococcus pneumoniae from a global surveillance program (2014).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29499898" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Ceftriaxone combination therapy versus respiratory fluoroquinolone monotherapy for community-acquired pneumonia: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31362351" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Cephalosporins: A Focus on Side Chains andβ-Lactam Cross-Reactivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32344946" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Cephalosporins' Cross-Reactivity and the High Degree of Required Knowledge. Case Report and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12604560" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Lack of synergy of erythromycin combined with penicillin or cefotaxime against Streptococcus pneumoniae in vitro.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21763343" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Immunomodulatory agents in the treatment of community-acquired pneumonia: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12567294" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15184200" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16355349" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Revisiting combination antibiotic therapy for community-acquired invasive Streptococcus pneumoniae pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29957272" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18198264" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : The presence of pneumococcal bacteremia does not influence clinical outcomes in patients with community-acquired pneumonia: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11268227" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16455824" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Impact of initial antibiotic choice on mortality from pneumococcal pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10950779" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in 5 countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27988089" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Predictors of Mortality Among U.S. Veterans With Streptococcus Pneumoniae Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32125282" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : DNA hypermethylation during tuberculosis dampens host immune responsiveness.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
